Metal-β-Lactamase
Freeze-dried powder,≥2 million units
- Product Code: 99111
Alias:
β-lactamase; penicillinase
CAS:
9073-60-3
| Molecular Weight: | Molecular Formula: | ||
|---|---|---|---|
| EC Number: | MDL Number: | MFCD00131819 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, dry, sealed |
Product Description:
Metal-β-lactamase inhibitors are primarily used in the medical field to combat antibiotic resistance, particularly in bacteria that produce β-lactamase enzymes. These enzymes can break down β-lactam antibiotics, rendering them ineffective. By inhibiting metal-β-lactamase, these compounds restore the efficacy of antibiotics like penicillins, cephalosporins, and carbapenems. They are often combined with β-lactam antibiotics to treat infections caused by multidrug-resistant bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii. This approach is critical in hospitals and clinical settings where resistant bacterial infections pose significant challenges to patient care. Additionally, research is ongoing to develop new inhibitors to address emerging resistance mechanisms and improve treatment outcomes.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to Off-White Solid, Powder, or Crystals |
| INSOLUBLE MATTER | Pass |
| PH RANGE | 7-8 |
| SOLUBILITY IN WATER | almost transparency |
| STERILITY | Pass |
| WATER BY KARL FISCHER | 0 5% |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 1.000 | 10-20 days | ฿1,980.00 |
+
-
|
Metal-β-Lactamase
Metal-β-lactamase inhibitors are primarily used in the medical field to combat antibiotic resistance, particularly in bacteria that produce β-lactamase enzymes. These enzymes can break down β-lactam antibiotics, rendering them ineffective. By inhibiting metal-β-lactamase, these compounds restore the efficacy of antibiotics like penicillins, cephalosporins, and carbapenems. They are often combined with β-lactam antibiotics to treat infections caused by multidrug-resistant bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii. This approach is critical in hospitals and clinical settings where resistant bacterial infections pose significant challenges to patient care. Additionally, research is ongoing to develop new inhibitors to address emerging resistance mechanisms and improve treatment outcomes.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :